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Abstract
Introduction: Reduced lung function in diabetes has been described for long but its clinical importance is not yet clear. Also, 
limited literature is available regarding its association with sugar control, and its correlation with inflammatory markers. Thus, we 
aimed to study the pulmonary function test abnormalities and systemic inflammation in type 2 diabetes mellitus.
Material and methods: 100 patients with type 2 diabetes were divided into two groups depending on control of diabetes (group 
A–HbA1C ≤ 7% and group B-HbA1C > 7%). All the subjects selected underwent detailed evaluation including testing for HbA1C, 
HsCRP (high-sensitivity C-reactive protein), serum ferritin and serum fibrinogen, along with pulmonary function testing. 
Results: Percentage predicted FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 second) and SVC (slow vital ca-
pacity) were significantly reduced, while mean values of inflammatory markers [fibrinogen (p < 0.001) and hsCRP (p < 0.002)] 
were significantly higher in uncontrolled diabetes group. There was a significant negative correlation between FEV1 (r = –0.739, p 
< 0.001), FVC (r = –0.370, p < 0.001), SVC (r = –0.635, p < 0.001) with HbA1C. HbA1C had a positive correlation with hsCRP 
(r = –0.308, p < 0.002) and fibrinogen (r = 0.388, p < 0.001). 
Conclusion: Pulmonary functions were decreased and inflammatory markers like hsCRP, fibrinogen, and ferritin significantly 
increased in uncontrolled diabetics. Also, a potential association was seen between higher values of inflammatory markers like 
hsCRP and fibrinogen and decrease in lung function. This information, requiring confirmation with larger multicentre studies, 
remains important because of potential epidemiological, clinical and therapeutic implications.
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Introduction
Diabetes mellitus is a public health problem 
and has reached an epidemic proportion. Micro-
vascular and macrovascular complications are 
the important cause of morbidity affecting va-
rious organ systems in diabetic patients. Several 
theories explain how glycosylation and oxidative 
stress leads to impaired collagen and elastin cross 
linkage with reduction in elasticity and strength 
of connective tissue which cause complications in 
diabetes. An extensive microvascular circulation 
and the abundant connective tissue in the lung 
raise the possibility that the lung may also be 
a target organ in diabetes [1]. Though an associa-
tion of reduced lung function with diabetes has 
been described for many years, the clinical signi-
ficance of this relationship is not yet known [2]. 
Some studies suggest that impaired lung function 
not only leads to increased respiratory morbidity, 
but also to adverse cardiovascular events and 
increased overall mortality [3, 4]. Systemic in-
flammatory activity also plays an important role 
in the pathogenesis of insulin resistance, and 
type 2 diabetes mellitus. It is likely that persistent 
inadequate glucose control over time may alter 
regulation of inflammatory pathways that are 
involved in the impairment of lung function [5]. 
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It is still unknown if inadequate glucose control 
in type 2 diabetes is simultaneously associated 
with a decrease in lung function and increased 
systemic levels of inflammatory markers. In this 
study, we compare type 2 diabetes subjects basing 
on their glucose control profile (adequate vs. ina-
dequate) and assess differences in lung functions 
(spirometry) and blood levels of the three known 
systemic inflammatory markers. Thus, the aims 
and objectives of the present study were the fol-
lowing: (1) to investigate the effect of type 2 dia-
betes mellitus on pulmonary function tests; (2) to 
correlate pulmonary function abnormalities with 
glycemic control; and (3) to study the association 
of pulmonary function abnormalities with sys-
temic inflammation in type 2 diabetes mellitus.
Material and methods
This prospective study was conducted in 
the Department of Internal Medicine of a tertiary
— care teaching institute in 100 type 2 diabetic 
patients (aged 30 to 65)
— attending the institute after ethical clearance 
was obtained from institutional ethical
— committee. Inclusion and exclusion criteria 
of the study subjects are shown in Table 1. 
Patients were classified into two groups 
A and B depending on control of diabetes:
I. Group A — 50 patients of type 2 diabetes 
with good control that is HbA1C ≤ 7%.
II. Group B — 50 patients of type 2 diabetes 
mellitus with poor glycemic control that is 
HbA1C > 7%.
For all the subjects selected for the purpose 
of the study, parameters like age, height (m), we-
ight (kg), body mass index (BMI) were measured. 
A structured pro forma was used to collect the 
relevant information regarding history, clinical 
findings and investigation test results of the 
patients.
All the subjects included in the study unde-
rwent following investigations:
1. Fasting blood sugar level, postprandial blood 
sugar level, HbA1C, HsCRP (high-sensitivity 
C-reactive protein, by Elisa method, quanti-
tative), serum ferritin (Elisa method), Serum 
fibrinogen (Fibri-prest method). 
2. Pulmonary function test (by MedisoftSpi-
roair). The spirometry report would take into 
account the predicted normal value for every 
subject.FVC (forced vital capacity), Forced 
expiratory volume in 1 second (FEV1),FEV1/
FVC, FEV1%( FEV1 as percentage of FVC), 
PEFR (peak expiratory flow rate), MMEF 
(maximum mid expiratory rate), SVC (slow 
vital capacity).
The statistical significance of categorical 
variables was determined by Chi-square test/
Fischer Exact Test for quantitative variable and 
unpaired‘t’ test/non-parametric Mann Whitney 
test. The correlation between PFT parameters 
and systemic inflammation was calculated by 
using Pearson Correlation Coefficient. Control-
led data was analyzed with the same use of SPSS 
statistical software. Master chart showing the 
basic characters of the controlled diabetes group 
and uncontrolled group was prepared and rear-
ranged as per the requirement to analyze the ef-
fect of HbA1C on PFT and inflammatory markers. 
The level of statistical significance was taken as 
p < 0.05.
Table 1. Inclusion and Exclusion criteria of study population
Inclusion Criteria Exclusion Criteria
All	patients	with	type	2	diabetic	patients	
in	the	age	group	of	30	to	65	years	be-
longing	to	either	sex	attending	OPD	and	
admitted	in	medical	wards
Smokers
Pregnant	females
BMI	>	30	kg/m2
History	of	respiratory	allergy	and	acute	respiratory	infection	in	the	previous	3	months.	Present	
or	past	history	of	respiratory	disease	that	might	affect	lung	function	such	as	asthma,	pleural	
effusion	/empyema,	pulmonary	tuberculosis,	COPD,	bronchiectasis,	Interstitial	lung	disease,		
lung	cancer	etc.	
Known	cardiovascular	diseases	like	congestive	cardiac	failure,	ischemic	heart	disease,	diastolic	
dysfunction
Previous	diagnosis	of	rheumatoid	arthritis	or	collagen	vascular	diseases,	antibiotics	use		
in	the	last	4	weeks
Patients	with	chest	deformities	that	would	preclude	conducting	a reliable		
a spirometric	procedure
Patients	with	deranged	renal	function	(serum	creatinine	≥	1.5	mg/dl)
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Table 3. Summary of pulmonary function tests in study groups
Variable Controlled diabetes group  
(n = 50)
(mean ± SD)
Uncontrolled diabetes group 
( n= 50)
(mean ± SD)
p-value
Percentage	predicted	FEV1
Percentage	predicted	FVC
Percentage	predicted	FEV1%
Percentage	predicted	PEFR
Percentage	predicted	SVC
Percentage	predicted	MMEF
100.1	±	21.8
101.95	±	18.1
97.97	±	12.5
115.48	±	63.49
83.62	±	14.82
86.72	±	16.50
80.27	±	22.5
69.36	±	15.34
99.27	±	12.9
91.14	±	46.46
63.99	±	13.31
82.85	±	12.54
<	0.001
<	0.001
0.612
0.031
<	0.001
0.095
Abbreviations	in	the	text
Table 2. Characteristics of diabetic patients at the baseline 
Number	of	Subjects 100
Age	(years)	Range 32	to	65
Sex	 57	males	and	43	females
Types	of	subjects 50	uncontrolled	type	2	DM,		
50	controlled	type	2	DM
DM	duration	(years)	 <	5	years:	22	patients
5–10	years:	38	patients	
>10	years:	40	patients
HbA1C	(Range) 5.3	to	13.7%
Results
We screened 110 subjects and 100 were fi-
nally included in the study (Table 2). The most 
frequent cause for exclusion was age (outside the 
stipulated inclusion criteria); past history of TB 
and smoking. Of the 100 studied type 2 diabetic 
subjects, 50 were classified as having uncontro-
lled diabetes (Group B, HbA1C > 7%) and the 
remaining 50 were in controlled diabetes group 
(Group A, HbA1C < 7%). The pulmonary function 
tests and blood investigations were conducted 
in 50 uncontrolled and 50 controlled diabetics.
Baseline characteristics
 The baseline characteristics of both groups 
were compared (Supplementary File). There were 
no statistically significant differences in sex, age, 
height, weight, BMI. But there was significant 
difference between both the groups in duration 
of diabetes.
Pulmonary function tests
 Various pulmonary function tests in diabetic 
patients are shown in Table 3. Percentage predic-
ted FVC, FEV1 and SVC were significantly reduced 
in the uncontrolled diabetes group compared to 
the controlled ones (Fig. 1).
Levels of inflammatory markers
 The mean values of inflammatory markers, 
fibrinogen and hsCRP were higher in uncontrolled 
diabetes than in controlled diabetes and it was 
statistically significant for hsCRP (p = 0.002) and 
fibrinogen (p < 0.001). Serum ferritin though was 
discovered to be higher in uncontrolled diabetes 
group was found to be statistically insignificant 
(p-value = 0.412) (Table 4).
Correlation studies
Following the above results, correlation was 
studied in details for FEV1, FVC, FEV1%, SVC with 
glycemic control and inflammatory markers (Ta-
ble 5). There was a negative correlation between 
FEV1 (r = –0.739,p<0.001), FVC ( r= –0.370,p < 
0.001), SVC (r = –0.635, p < 0.001) with HbA1C 
which were statistically significant. FEV1% (r = 
0.107, p = 0.291) ratio had statistically insigni-
ficant correlation with HbA1C. Thus it implies 
that as the HbA1C value rises there is a decrease 
in FEV1, FVC and SVC values.
With respect to correlation of glycemic con-
trol with inflammatory markers, HbA1C has 
a positive correlation with hsCRP (r = –0.308, 
p = 0.002) and fibrinogen (r = 0.388, p = 0.001) 
which were statistically significant and statisti-
cally insignificant correlation with ferritin(r = 
0.076, p < 0.453) (Table 5). Thus as the HbA1C 
rises there is significant increase in levels of 
hsCRP and fibrinogen but not in ferritin levels.
There was a negative correlation of FVC, 
FEV1, and SVC with hsCRP and fibrinogen which 
was statistically significant. There was statisti-
cally insignificant correlation of FVC, FEV1, and 
SVC with ferritin (Table 6). The FEV1% had a sta-
tistically insignificant correlation with hsCRP, 
ferritin, and fibrinogen. Thus, as FVC, FEV1, SVC 
decreased, there was an associated increase in 
inflammatory markers like hsCRP and fibrinogen 
concentration.
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Figure 1. Mean	values	of	Pulmonary	Function	tests	in	both	study	groups	(controlled	vs	uncontrolled	diabetic	subjects);	abbreviations	in	the	text
Table 4. Summary of inflammatory markers in both groups
Marker Controlled diabetes group  
(n = 50)
(mean ± SD)
Uncontrolled diabetes group  
(n= 50)
(mean ± SD)
p-palue
hsCRP	(mg/l)
Ferritin	(ug/l)
Fibrinogen	(mg	/dl)
2.5	±	1.1
93.09	±	44.8
295.02	±	31.27
3.24	±	1.08
96.72	±	34.28
324.22	±	41.56
0.002
0.412
<	0.001
Table 5. Correlation of glycemic control with pulmonary function tests and inflammatory markers in diabetes patients
Glycemic control Pulmonary function tests Pearson correlation p-value
HbA1C
FEV1
FVC
FEV1%
SVC
–0.739
–0.370
0.107
–0.635
<	0.001
<	0.001
0.291
<	0.001
Inflammatory markers Pearson correlation p-value
HbA1C hsCRP
Ferritin
Fibrinogen
0.308
0.076
0.388
0.002
0.453
0.001
Discussion
India is one of the two major global hubs for 
the rapidly escalating type 2 diabetes epidemic, 
along with China. Till now pulmonary compli-
cations of diabetes were least studied and the 
exact etiology of pulmonary complication is still 
not known. So far most of the studies come from 
western world and only few investigations have 
been conducted in India regarding pulmonary 
complications of type 2 DM [6–10].
In the present study one hundred examined 
type 2 diabetes patients were divided in two gro-
ups, controlled diabetes group and uncontrolled 
diabetes group. The basic characteristics like age, 
gender, height, weight, BMI in our study groups 
were analyzed and were found to be comparable. 
Respiratory parameters such as percentage pre-
dicted FVC, FEV1, FEV1%, SVC, MMEF, and PEFR 
were recorded in both the groups. Percentage 
predicted FVC, FEV1 and SVC were significantly 
reduced in the uncontrolled diabetes group com-
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Table 6. Correlation of pulmonary function tests (PFTs) 
and inflammatory markers
PFTs Inflammatory  
markers
Pearson  
correlation
r value
p-value
FVC
hsCRP
Ferritin
Fibrinogen
–0.393
–0.105
–0.550
<	0.001
0.297
<	0.001
FEV1
hsCRP
Ferritin
Fibrinogen
–0.310
0.012
–0.47
<	0.002
0.905
<	0.001
FEV1%
hsCRP
Ferritin
Fibrinogen
–0.166
–0.073
–0.73
0.100
0.472
0.471
SVC hsCRP
Ferritin
Fibrinogen
–0.377
–0.053
–0.397
<	0.001
0.60
<	0.001
Abbreviations	in	the	text
pared to the controlled diabetes group. Percentage 
predicted MMEF was mildly lowered in both the 
groups but the reduction was not statistically si-
gnificant (p-value < 0.095). Percentage predicted 
FEV1 % was greater in the uncontrolled group 
but the increase was statistically insignificant 
(p-value < 0.612). A reduction in vital capacity 
as evidenced by a  fall in SVC, FVC and FEV1, 
with normal FEV1% is suggestive of a tendency 
towards a restrictive ventilatory pattern. Percen-
tage predicted PEFR was also reduced in both 
the groups that is controlled and uncontrolled 
diabetes groups but reduction was greater in the 
uncontrolled group and the decrease was stati-
stically significant (p-value < 0.031). As the ob-
servations made above are indicative of primarily 
restrictive ventilatory pattern of lung disorder and 
in this group of disorder PEFR and MMEF have 
an insignificant role. On correlating pulmonary 
functions with glycemic control we found that 
there was a negative correlation between FEV1 
(r = –0.739, p < 0.001), FVC (r= –0.370, p < 0.001) 
and SVC (r= –0.635, p <0.001) and HbA1C and 
it was statistically significant. This indicates that 
as the glycemic control worsens the pulmonary 
functions decline. FEV1/FVC (r = 0.107, p 0.291) 
ratio had insignificant correlation with HbA1C.
Our findings were in accordance with previous 
studies. Framingham Heart study by Walter et al. [11], 
demonstrated reduction of FVC, FEV1 and an in-
crease in FEV1/FVC ratio in diabetic patients sug-
gesting a restrictive pattern of ventilatory impair-
ment]. The lung functions decreased as the serum 
glucose concentration increased. In another study 
by Davis et al. [12], it was demonstrated that mean 
percentage predicted values of each spirometric 
measure decreased by 10% in the whole cohort 
at baseline and absolute measures continued to 
decline at an annual rate of 68, 71, and 84 ml/
year and 17 l/min for FVC, FEV1, VC, and PEF 
respectively, in the 125 prospectively studied 
patients. Declining lung function measures were 
consistently predicted by poor glycemic control 
in the form of a higher updated mean HbA1C, 
follow-up HbA1C, or follow-up fasting plasma 
glucose. Keerthi et al. [6] studied 50 type 2 dia-
betes mellitus patients and 50 healthy controls in 
India and found decrease in pulmonary function 
tests in diabetics as compared to nondiabetics. 
They also found that females were more prone 
to respiratory dysfunction than male diabetics. 
Study by Verma et al. [7] also showed restrictive 
type of pulmonary ventilatory impairment as 
evidenced by significant reduction in FVC, FEV1, 
and normal FEV1/FVC in type-2 diabetes patients. 
The diabetic lung is best characterized as 
a loss of physiological reserves. There are diffe-
rent hypotheses that explain the reduced spiro-
metric measurements in diabetics. Preliminary 
reports of histopathologic changes in the lungs 
of diabetic patients reveal basal lamina thicke-
ning and fibrosis [13, 14]. In both human and 
animal studies, diabetic lungs have demonstrated 
diabetic microangiopathy of the alveolar sep-
tal capillaries, with a  thickened epithelial and 
capillary basement membrane, and increased 
extracellular matrix and connective tissue [15]. 
In diabetic patients, chronic hyperglycemia can 
bring about a rise in collagen molecule synthesis 
and cross-linking via the acceleration of advanced 
glycation end-products, which can also negatively 
influence lung function [16, 17].
Despite the unclear nature of the direction of 
association between diabetes and lung dysfunc-
tion, this relationship remains important because 
of potential epidemiological, clinical and thera-
peutic implications. Although the magnitude of 
lung function impairment secondary to diabetes 
is likely to cause only subclinical abnormalities, 
a loss of pulmonary reserve capacity may become 
clinically important in the context of superimpo-
sed conditions, such as age-related lung function 
decline, obesity, smoking, hypoxia associated 
with acute or chronic disease or fluid overload 
secondary to cardiac or renal failures which are 
common complications of diabetes [18]. Similarly, 
the impairment in lung function seen in patients 
with diabetes can lower the threshold for clinical 
manifestations of acute or chronic lung diseases. 
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In a study by Ehrlich et al. [19], it was reported 
that diabetics are at increased risk of several pul-
monary condititions (asthma, COPD, fibrosis and 
pneumonia) but not lung cancer and this may be 
due to declining lung function. 
Inflammatory markers in diabetes: The levels 
of hsCRP were higher in the controlled diabetes 
than the concentration of hsCRP in the contro-
lled group with p-value of 0.002. Thus, there is 
a significant increase in hsCRP in the uncontrol-
led diabetes group. The study group was further 
divided into high risk and moderate and low risk 
patients basing on their hsCRP levels. Among the 
study group 13 subjects in the controlled diabetes 
group and 38 from uncontrolled diabetes group fell 
into high risk (hsCRP > 3 mg/dl) category. Thus 
there is a statistically significant increase in the 
number of high risk patients in the uncontrolled 
diabetes group (p = 0.002) There was also a stati-
stically significant increase in the levels of fibrino-
gen in the uncontrolled diabetes group compared 
to controlled diabetes with a p-value of < 0.001.
There was an increase in the levels of ferritin 
in uncontrolled group compared to the controlled 
group but the difference was not statistically si-
gnificant (p-value = 0.412). Since ferritin levels 
are known to be different in two genders i.e. 
males and females, both the groups were further 
subdivided into males and females and were 
compared. It was found that ferritin levels were 
significantly raised in females in the uncontrol-
led group in comparison to the controlled group 
(p = 0.005) whereas the raise was not statistically 
significant in males (p = 0.780). 
In our study HbA1C had a positive corre-
lation with hsCRP and fibrinogen which was 
statistically significant. HbA1C had an insigni-
ficant correlation with ferritin. Thus there is 
a significant increase in inflammatory markers 
like hsCRP and fibrinogen as the HbA1C rises.
Various studies in the past have found associa-
tion between inflammation and diabetes [3, 5]. 
Pitsavos et al. [20] in the ATTICA study support 
a positive association between low-grade inflam-
mation (TNF alpha and hsCRP) and diabetes in 
a population-based sample of men and women 
without any evidence of cardiovascular disease. 
Correlation of lung functions with inflamma-
tory markers: There was a negative correlation of 
FVC, FEV1, and SVC with hsCRP and fibrinogen 
which was statistically significant. There was 
statistically insignificant correlation of FVC, 
FEV1, and SVC with ferritin. The FEV1% had a sta-
tistically insignificant correlation with hsCRP, 
ferritin, and fibrinogen. Thus from the above 
results it can be concluded that as FVC, FEV1, 
SVC decreases there is an associated increase 
in inflammatory markers like hsCRP, fibrinogen 
levels. In summary, subjects with uncontrolled 
diabetes also had significantly higher levels of 
inflammatory markers (fibrinogen, and hsCRP), 
along with decreased lung functions.
Dennis et al in their study involving diabetic 
patients concluded that diabetic subjects with 
inadequate control had lower FVC and FEV1 than 
those with adequate control and also had signi-
ficantly higher levels of inflammatory mediators 
like ferritin, hsCRP, fibrinogen and TNF-a sugge-
sting a potential association [5]. Though our study 
had similar findings with hsCRP and fibrinogen, 
there was no significant correlation with serum 
ferritin and lung dysfunction.
Limitation of our study was its cross sectional 
hence only one measurement of HbA1C was done 
to ascertain glycemic control restricting its use-
fulness in labelling disease control. In addition, 
PFT was limited to spirometry alone.
Conclusions
To conclude, our findings not only have confir-
med that diabetic subjects show reduction in pul-
monary functions which is higher in patients with 
inadequate glucose control but also have showed 
that Indian diabetic subjects with inadequate control 
also had significantly higher levels of inflammation 
markers (fibrinogen and hsCRP). There was also an 
increase in inflammatory markers like hsCRP and 
fibrinogen with decrease in lung function suggesting 
a potential association. Our results need to be con-
firmed by longitudinal studies (given that diabetic 
control is a time-dependent variable). Detailed lung 
functions including diffusion studies can be investi-
gated in future for better understanding of the diabetic 
lung dysfunction. Hopefully, it can also be shown that 
better glucose control can result not only in lack of fur-
ther decrease in lung function but also in attenuation 
of the inflammatory response. Our findings, however, 
should make clinicians more aware of this association 
and add to the necessity of advising diabetic patients 
of the need for adequate glucose control.
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